1. In Vivo

Tumbling Medtech Investment Records Leave A Hill To Climb In 2022

‘Superlative’ Best Describes Medtech And Healthtech Deal Activity And Performance In 2021

 
• By Ashley Yeo

Listing all-time high medtech IPO and M&A activity, Silicon Valley Bank’s 2021 health care investments and exits report made good reading after the market uncertainties induced by the pandemic a year earlier. But where does the sector go now after such a sterling year?

alamy

Investment in health care companies in the US and Europe in 2021 reached $86.3bn, according to the latest annual investments and exits update from Silicon Valley Bank (SVB). This was a heady 64% up on the 2020 performance, with healthtech – up 157% ̶ leading the way.

Elsewhere, record numbers of medical device IPOs (24) and private M&A deals (those with at least $50m upfront) were reported...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.